Pantoprazole-Domperidone Induced Hyperprolactinemia and Galactorrhea in a Chronic Kidney Disease Patient on Dialysis
Published: 2021-12-29
Page: 125-128
Issue: 2021 - Volume 4 [Issue 1]
Deepak Kumar Chitralli
Department of Nephrology and Transplant, Columbia Asia Hospital, Yeshwantpur, Bengaluru 560055, India.
Anu Ann Abraham
Columbia Asia Hospital, Yeshwantpur, Bengaluru 560055, India.
Brian Mark Churchill *
PG Certificate Transplantation (Liverpool University), FASN / Medical Science and Strategy (Asia), IQVIA, Omega, Embassy Tech Square, Marathahalli - Sarjapur Outer Ring Road, Kadubeesanahalli, Bengaluru 560103, India.
Rajeshwari Janakiraman
Columbia Asia Hospital, Yeshwantpur, Bengaluru 560055, India.
*Author to whom correspondence should be addressed.
Abstract
Pantoprazone-Domperidone fixed-dose combinations are commonly used in End Stage Renal Disease (ESRD) patients on dialysis. The medication helps in control of drug induced gastritis that can occur due to several medications including oral calcium and iron supplements. Besides this the pantoprazole-domperidone combination helps in treatment of uremic gastritis, peptic ulcer disease, and gastroesophageal reflux disease.
Rarely, pantoprazole and domperidone may induce galactorrhea. We report a case of a female patient on dialysis who developed drug induced hyperprolactinemia and galactorrhea due to therapeutic dose of a fixed-dose combination of pantoprazole (40 mg) and domperidone (30 mg), used for treatment of gastritis- the duration of therapy being 4 months. Galactorrhea subsided after discontinuation of pantoprazole-domperidone.
Keywords: Hyperprolactinemia, galactorhea, pantoprazole, domperidone, domperidone combination.